Engrail Therapeutics 获得 1.57 亿美元 B 轮融资，用于焦虑、抑郁和神经退行性疾病治疗。 Engrail Therapeutics secures $157M Series B funding for anxiety, depression, and neurodegenerative disease therapies.

神经科学公司 Engrail Therapeutics 获得由 F-Prime Capital、Forbion 和 Norwest Venture Partners 领投的 1.57 亿美元 B 轮融资。 Neurosciences firm Engrail Therapeutics secures $157M Series B funding led by F-Prime Capital, Forbion, and Norwest Venture Partners. 该公司总部位于圣地亚哥，专注于开发焦虑症、抑郁症、创伤后应激障碍和罕见神经退行性疾病的疗法。 The company, based in San Diego, focuses on developing therapies for anxiety disorders, depression, post-traumatic stress disorder, and rare neurodegenerative diseases. 该轮融资的收益将用于推进其产品线通过多个临床开发阶段。 Proceeds from the round will be used to advance its pipeline through multiple stages of clinical development.